Jeff Aronin, CEO of Paragon Biosciences, Is Moving Medicine Forward

With more than 20 years of experience in creating dynamic biotech and pharmaceutical companies, Jeff Aronin is a true pioneer in healthcare, and in helping patients prevail over serious illnesses (Alivenewspaper).

Leading Paragon Biosciences since 2010, Jeff Aronin has helped further establish a new paradigm in biotech, which has led to a focused, patient-centric drug development strategy. The strategy helps to more efficiently bring forward important science for patients with unmet needs.

Paragon and its portfolio companies are focused on understanding the underlying cause of diseases, especially those affecting people who have few or no treatment options. The team then seeks breakthrough science, partnering with innovative researchers around the world to identify novel ways to address serious illness. Once that is accomplished, Paragon sets out to finance and incubate promising biotech companies that are focused on bringing medicines to market.

Two of Paragon’s lead companies are Castle Creek Pharmaceuticals and Harmony Biosciences. Castle Creek is focused on rare genetic dermatology disorders and Harmony is focused on central nervous system disorders. Whether it is addressing the underlying causes of epidermolysis bullosa simplex (in the case of Castle Creek) or narcolepsy and cataplexy (in the case of Harmony), Paragon’s companies are doing important work to bring additional options for patents in need.

Beyond Paragon, Jeff Aronin has nearly two decades of experience in the biotech industry spent discovering and developing medicines that have helped tens of thousands of patients live better. At Paragon, the leadership team has secured 13 new drug approvals, a rate on par with or better than most large biotech and pharma companies.

Paragon Biosciences partners with top medical professionals to do the important clinical research needed to get medicines approved. Jeff and his team put patients first and work every day to do the most they can to develop medicines that matter.

That commitment to patients, innovation, philanthropy and entrepreneurship led the Weizmann Institute to bestow its 2017 leadership award upon Jeff Aronin, though as he is quick to point out, any success in science is truly a team effort that ultimately benefits patients.